US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

WisdomTree Global ex U.S. Quality Dividend Growth Fund

43.47

+0.59501.39%

Volume:14.57K

Turnover:631.29K

Market Cap:482.46M

PE:- -

High:43.47

Open:43.20

Low:43.20

Close:42.87

52wk High:45.33

52wk Low:31.71

Shares:11.10M

Float Shares:11.10M

Volume Ratio:1.08

T/O Rate:0.13%

Dividend:0.85

Dividend Rate:1.95%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

With 52% ownership in Dyno Nobel Limited (ASX:DNL), institutional investors have a lot riding on the business

Simply Wall St.

Insufficient Growth At Dyno Nobel Limited (ASX:DNL) Hampers Share Price

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/DNL"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DNL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DNL\",,,,,undefined,":{"symbol":"DNL","market":"US","secType":"STK","nameCN":"WisdomTree Global ex U.S. Quality Dividend Growth Fund","latestPrice":43.465,"timestamp":1770656596377,"preClose":42.87,"halted":0,"volume":14565,"delay":0,"changeRate":0.013879169582458736,"floatShares":11100000,"shares":11100000,"eps":0,"marketStatus":"Trading","change":0.595,"latestTime":"02-09 12:10:34 EST","open":43.2,"high":43.47,"low":43.2,"amount":631292.68845,"amplitude":0.006298,"askPrice":43.5,"askSize":121,"bidPrice":43.04,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770670800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":42.87,"sharesOutstanding":11100000,"nav":41.969517,"aum":461466524.87,"dividendRate":0.019528,"bidAskSpread":0.0022,"postHourTrading":{"tag":"盘后","latestPrice":42.87,"preClose":42.87,"latestTime":"16:10 EST","volume":7,"amount":300.09,"timestamp":1770412204258,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.081411,"impliedVol":0.043,"impliedVolPercentile":0.2151},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DNL\",,,,,undefined,":{"symbol":"DNL","floatShares":11100000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.081411,"shares":11100000,"dividePrice":0.8488,"high":43.47,"amplitude":0.006298,"preClose":42.87,"low":43.2,"week52Low":31.7068,"pbRate":"--","week52High":45.33,"institutionHeld":0,"latestPrice":43.465,"committee":-0.095023,"eps":0,"divideRate":0.019528,"volume":14565,"delay":0,"ttmEps":0,"open":43.2,"prevYearClose":41.22,"prevWeekClose":42.87,"prevMonthClose":42.87,"prevQuarterClose":41.22,"fiveDayClose":43.0887,"twentyDayClose":43.25,"sixtyDayClose":41.3491},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DNL\",params:#limit:5,,,undefined,":[{"date":"2025-12-26","symbol":"DNL","amount":0.23418,"announcedDate":"2025-12-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-26","defaultRemindTime":1766759400000,"name":"WisdomTree Global ex U.S. Quality Dividend Growth Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-30","payableDate":"2025-12-26","currency":"USD","dateTimestamp":1766725200000,"payDate":"2025-12-30"},{"date":"2025-09-25","symbol":"DNL","amount":0.17,"announcedDate":"2025-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-25","defaultRemindTime":1758807000000,"name":"WisdomTree Global ex U.S. Quality Dividend Growth Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-25","currency":"USD","dateTimestamp":1758772800000,"payDate":"2025-09-29"},{"date":"2025-06-25","symbol":"DNL","amount":0.33,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"WisdomTree Global ex U.S. Quality Dividend Growth Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-06-27"},{"date":"2025-03-26","symbol":"DNL","amount":0.115,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"WisdomTree Global ex U.S. Quality Dividend Growth Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-28"},{"date":"2024-12-31","symbol":"DNL","amount":0.08623,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-31","defaultRemindTime":1735655400000,"name":"WisdomTree Global ex U.S. Quality Dividend Growth Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-03","payableDate":"2024-12-31","currency":"USD","dateTimestamp":1735621200000,"payDate":"2025-01-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DNL\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-21","recordDate":"2016-03-23","paymentDate":"2016-03-28","value":0.095,"currency":"USD"},{"executeDate":"2016-06-20","recordDate":"2016-06-22","paymentDate":"2016-06-24","value":0.485,"currency":"USD"},{"executeDate":"2016-09-26","recordDate":"2016-09-28","paymentDate":"2016-09-30","value":0.395,"currency":"USD"},{"executeDate":"2016-12-23","recordDate":"2016-12-28","paymentDate":"2016-12-30","value":0.18202,"currency":"USD"},{"executeDate":"2017-03-27","recordDate":"2017-03-29","paymentDate":"2017-03-31","value":0.15,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DNL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DNL\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608866680","title":"Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2608866680","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608866680?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033600,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Feb.  02, 2026  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/02/3230125/0/en/Sagimet-Announces-Positive-52-Week-Data-from-License-Partner-Ascletis-Open-Label-Phase-3-Clinical-Trial-Evaluating-the-Long-Term-Safety-of-ASC40-Denifanstat-Tablets-in-Patients-wit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNL","IGA"],"gpt_icon":0},{"id":"2607208545","title":"Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2607208545","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607208545?lang=en_us&edition=fundamental","pubTime":"2026-01-29 19:00","pubTimestamp":1769684400,"startTime":"0","endTime":"0","summary":"- Denifanstat , aonce-daily oral fatty acid synthase  inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study. - The exceptional efficacy of denifanstat  observed in the Company's previously reported placebo-controlled Phase III trial coupled with a favorable safety profile in two Phase III trials provide a potential major break-through for the treatment of acne. - New Drug Application for denifanstat  for acne was recently accepted by the China National Medical Products Administration. HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc.  today announced positive topline results from the Phase III open-label study  evaluating denifanstat , a first-in-class, once-daily oral small molecule fatty acid synthase  inhibitor, in patients with moderate-to-severe acne vulgaris.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-announces-positive-topline-results-from-its-phase-iii-open-label-study-of-denifanstat-asc40-a-first-in-class-once-daily-oral-fasn-inhibitor-for-acne-302673870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK7025","DNL","BK4134","DNL.AU"],"gpt_icon":0},{"id":"2606272751","title":"With 52% ownership in Dyno Nobel Limited (ASX:DNL), institutional investors have a lot riding on the business","url":"https://stock-news.laohu8.com/highlight/detail?id=2606272751","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606272751?lang=en_us&edition=fundamental","pubTime":"2026-01-28 04:54","pubTimestamp":1769547268,"startTime":"0","endTime":"0","summary":"Key Insights Institutions' substantial holdings in Dyno Nobel implies that they have significant influence over the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2022000-choice1-main-header/1585186586604","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2022000-choice1-main-header/1585186586604"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-dnl/dyno-nobel-shares/news/with-52-ownership-in-dyno-nobel-limited-asxdnl-institutional","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-dnl/dyno-nobel-shares/news/with-52-ownership-in-dyno-nobel-limited-asxdnl-institutional","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DNL.AU","DNL","BK7025"],"gpt_icon":0},{"id":"2602583980","title":"Insufficient Growth At Dyno Nobel Limited (ASX:DNL) Hampers Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2602583980","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602583980?lang=en_us&edition=fundamental","pubTime":"2026-01-10 04:14","pubTimestamp":1767989653,"startTime":"0","endTime":"0","summary":"Dyno Nobel Limited's ( ASX:DNL ) price-to-sales (or \"P/S\") ratio of 1.6x might make it look like a strong buy right now...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2022000-choice1-main-header/1585186586604","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2022000-choice1-main-header/1585186586604"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-dnl/dyno-nobel-shares/news/insufficient-growth-at-dyno-nobel-limited-asxdnl-hampers-sha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-dnl/dyno-nobel-shares/news/insufficient-growth-at-dyno-nobel-limited-asxdnl-hampers-sha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DNL.AU","BK7025","DNL"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DNL\",params:#limit:6,delay:false,,,undefined,":[]}}